Replies to post #186684 on Biotech Values

[pollyvonwog]

So per my shoddy math ABBV seems to have locked up a solid 33-35% of the hcv population in preferred deals, no?

ESRX = 8-10%
co-infected HIV/HCV population = 10%
Medicaid deal = 15% (Using Merrill 30% number as baseline here).

[shareholder_boar]

"25-state Medicaid consortium picks Viekira Pak as preferred HCV option.."

The WSJ article suggests that only one member of the consortium has committed to AbbVie:

"An AbbVie spokeswoman declined to provide terms of the agreement with Missouri or the status of Viekira Pak coverage or negotiations in other states.

A spokesman for Connecticut’s department of social services said the state is “awaiting further information on costs and rebate amounts, and will make a decision on which product to prefer in several weeks.”"

Also seems that Gilead will not easily give up patients in the other consortium states:

"A Gilead spokeswoman said the company is negotiating with the 24 other states in the consortium to increase access to its medications for more Medicaid patients, in an effort to “allow physicians and patients access to a range of choices, rather than having to use a specific regimen.”"